急性冠脉综合征的抗血小板治疗.pptVIP

This slide kit provides an overview of the extensive research and development program investigating the role of clopidogrel (Plavix?/Iscover?) and antiplatelet therapy across a wide spectrum of patients at risk of atherothrombotic events. Over time, more than 100,000 at-risk patients will be included into a series of major clinical trials with clopidogrel, with treatment follow-up varying from at least four weeks to up to 42 months. Once completed, the clopidogrel clinical trial program will be one of the largest clinical trial programs ever developed for one single molecule. * 急性冠脉综合征（